PURPOSE: To describe cytomegalovirus (CMV) end-organ disease (EOD) rate in AIDS patients with low CD4+ cell count despite HAART who were enrolled in a randomized, placebo-controlled trial of preemptive valganciclovir (VGCV) to prevent CMV EOD in those with CMV viremia. METHODS: Subjects (N = 338) were HIV-infected with CD4+ count <100 cells/mm3, plasma HIV RNA >400 copies/mL, and on stable or no HAART. All underwent plasma CMV DNA PCR testing every 8 weeks (Step 1); those with detectable CMV DNA were randomized to VGCV or placebo (Step 2). RESULTS:Plasma CMV DNA was detected in 68 (20%), of whom 4 developed CMV EOD. During Step 1, 53 died. Of the 47 who entered Step 2 (24 VGCV, 23 placebo), CMV EOD was diagnosed in 10 (4 VGCV, 6 placebo) and 15 died (7 VGCV, 8 placebo). Of those randomized to placebo, 14% were diagnosed with CMV EOD at 12 months. CONCLUSIONS: We observed a lower CMV EOD rate among subjects receiving HAART than predicted based on published literature. However, mortality was high in this study. Our findings suggest that preemptive anti-CMV therapy in patients with persistently low CD4+ cell counts in the current treatment era may not be warranted given the low incidence of CMV EOD and high all-cause mortality observed in this study population.
RCT Entities:
PURPOSE: To describe cytomegalovirus (CMV) end-organ disease (EOD) rate in AIDSpatients with low CD4+ cell count despite HAART who were enrolled in a randomized, placebo-controlled trial of preemptive valganciclovir (VGCV) to prevent CMV EOD in those with CMV viremia. METHODS: Subjects (N = 338) were HIV-infected with CD4+ count <100 cells/mm3, plasma HIV RNA >400 copies/mL, and on stable or no HAART. All underwent plasma CMV DNA PCR testing every 8 weeks (Step 1); those with detectable CMV DNA were randomized to VGCV or placebo (Step 2). RESULTS: Plasma CMV DNA was detected in 68 (20%), of whom 4 developed CMV EOD. During Step 1, 53 died. Of the 47 who entered Step 2 (24 VGCV, 23 placebo), CMV EOD was diagnosed in 10 (4 VGCV, 6 placebo) and 15 died (7 VGCV, 8 placebo). Of those randomized to placebo, 14% were diagnosed with CMV EOD at 12 months. CONCLUSIONS: We observed a lower CMV EOD rate among subjects receiving HAART than predicted based on published literature. However, mortality was high in this study. Our findings suggest that preemptive anti-CMV therapy in patients with persistently low CD4+ cell counts in the current treatment era may not be warranted given the low incidence of CMV EOD and high all-cause mortality observed in this study population.
Authors: D J Lang; A A Kovacs; J A Zaia; G Doelkin; J C Niland; L Aledort; S P Azen; M A Fletcher; J Gauderman; G J Gjerset Journal: J Acquir Immune Defic Syndr (1988) Date: 1989
Authors: D Salmon-Céron; M C Mazeron; S Chaput; N Boukli; B Senechal; N Houhou; C Katlama; S Matheron; A M Fillet; J Gozlan; C Leport; V Jeantils; F Freymuth; D Costagliola Journal: AIDS Date: 2000-05-26 Impact factor: 4.177
Authors: J L Casado; J Arrizabalaga; M Montes; P Martí-Belda; C Tural; J Pinilla; C Gutierrez; J Portu; R Schuurman; K Aguirrebengoa Journal: AIDS Date: 1999-08-20 Impact factor: 4.177
Authors: Jane R Deayton; Caroline A Prof Sabin; Margaret A Johnson; Vincent C Emery; Pauline Wilson; Paul D Griffiths Journal: Lancet Date: 2004-06-26 Impact factor: 79.321
Authors: Adriana Weinberg; Ronald Bosch; Kara Bennett; Adriana Tovar-Salazar; Constance A Benson; Ann C Collier; Andrew Zolopa; Roy M Gulick; David Wohl; Bruce Polsky; Alejo Erice; Mark A Jacobson Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: David A Wohl; Michelle A Kendall; Judith Feinberg; Beverly Alston-Smith; Susan Owens; Suzette Chafey; Michael Marco; Sharon Maxwell; Constance Benson; Philip Keiser; Charles van der Horst; Mark A Jacobson Journal: PLoS One Date: 2013-11-15 Impact factor: 3.240